316 related articles for article (PubMed ID: 23592524)
1. Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
Massimino K; Harrskog O; Pommier S; Pommier R
J Surg Oncol; 2013 Jun; 107(8):842-6. PubMed ID: 23592524
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis.
Condron ME; Pommier SJ; Pommier RF
Surgery; 2016 Jan; 159(1):358-65. PubMed ID: 26603846
[TBL] [Abstract][Full Text] [Related]
3. Development of effective prophylaxis against intraoperative carcinoid crisis.
Woltering EA; Wright AE; Stevens MA; Wang YZ; Boudreaux JP; Mamikunian G; Riopelle JM; Kaye AD
J Clin Anesth; 2016 Aug; 32():189-93. PubMed ID: 27290972
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
5. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.
Kinney MA; Warner ME; Nagorney DM; Rubin J; Schroeder DR; Maxson PM; Warner MA
Br J Anaesth; 2001 Sep; 87(3):447-52. PubMed ID: 11517130
[TBL] [Abstract][Full Text] [Related]
6. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
[TBL] [Abstract][Full Text] [Related]
7. Orthotopic liver transplantation for carcinoid tumour metastatic to the liver: anesthetic management.
Claure RE; Drover DD; Haddow GR; Esquivel CO; Angst MS
Can J Anaesth; 2000 Apr; 47(4):334-7. PubMed ID: 10764178
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of Octreotide: Clinical Implications for Anesthesiologists and Associated Risks.
Borna RM; Jahr JS; Kmiecik S; Mancuso KF; Kaye AD
Anesthesiol Clin; 2017 Jun; 35(2):327-339. PubMed ID: 28526153
[TBL] [Abstract][Full Text] [Related]
9. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
Le BT; Bharadwaj S; Malinow AM
Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
[TBL] [Abstract][Full Text] [Related]
10. Partial hepatic resections for metastatic neuroendocrine tumors: perioperative outcomes.
Kinney MAO; Nagorney DM; Clark DF; O'Brien TD; Turner JD; Marienau ME; Schroeder DR; Martin DP
J Clin Anesth; 2018 Dec; 51():93-96. PubMed ID: 30098573
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery in patients with advanced-stage carcinoid tumors.
Gulec SA; Mountcastle TS; Frey D; Cundiff JD; Mathews E; Anthony L; O'Leary JP; Boudreaux JP
Am Surg; 2002 Aug; 68(8):667-71; discussion 671-2. PubMed ID: 12206599
[TBL] [Abstract][Full Text] [Related]
12. Management of patients undergoing multivalvular surgery for carcinoid heart disease: the role of the anaesthetist.
Castillo JG; Filsoufi F; Adams DH; Raikhelkar J; Zaku B; Fischer GW
Br J Anaesth; 2008 Nov; 101(5):618-26. PubMed ID: 18689806
[TBL] [Abstract][Full Text] [Related]
13. Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
Orbach-Zinger S; Lombroso R; Eidelman LA
Can J Anaesth; 2002; 49(7):678-81. PubMed ID: 12193484
[TBL] [Abstract][Full Text] [Related]
14. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
15. Discussion.
Surgery; 2016 Jan; 159(1):365-7. PubMed ID: 26603855
[No Abstract] [Full Text] [Related]
16. Primary hepatic carcinoid tumor with carcinoid syndrome and carcinoid heart disease: a case report of a patient on long-term follow-up.
Tohyama T; Matsui K; Kitagawa K
Intern Med; 2005 Sep; 44(9):958-62. PubMed ID: 16258211
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
Anthony L; Vinik AI
Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
[TBL] [Abstract][Full Text] [Related]
18. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
19. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
Katakami N; Matsumoto H; Ishihara K; Umeda B
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors.
Søreide O; Berstad T; Bakka A; Schrumpf E; Hanssen LE; Engh V; Bergan A; Flatmark A
Surgery; 1992 Jan; 111(1):48-54. PubMed ID: 1728075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
